Subscribe
shutterstock_1318400090_the_firstfotolab
16 January 2024AmericasMarisa Woutersen

SCOTUS urged to remedy ‘threat’ to patent law in sleep drug feud

Biotech company submitted a petition challenging an ‘incorrect’ ruling by the Court of Appeals for the Federal Circuit | Earlier decision invalidated several of Vanda’s patents in its sleep drug dispute against a pair of big pharma firms.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.
Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More on this story

Americas
Amgen v Sanofi: Scotus grapples with enablement
28 March 2023   As the US Supreme Court probed the key issue of enablement in Amgen v Sanofi, patent lawyers shared their views on the much-anticipated hearings.
Americas
Gilead avoids $1.2bn patent clash at SCOTUS
10 January 2023   Subsidiary held that its arguments were same as those cited in the much-anticipated Amgen v Sanofi | Dispute concerns a cancer treatment used to treat B-cell lymphoma.

More features

Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
Novo Nordisk files fresh lawsuits to intercept Wegovy generics
HLK adds CRISPR specialist as partner
UPC delivers first 'imminent infringement' decision in biosimilar dispute